BIO, PhRMA Ask Fed. Circ. To Revisit Double-Patent Ruling
Biotechnology Industry Organization and The Pharmaceutical Research and Manufacturers of America have told the Federal Circuit that its recent decision in a lawsuit over flu drug Tamiflu expanded the double-patent doctrine...To view the full article, register now.
Already a subscriber? Click here to view full article